罗格列酮治疗前后糖尿病并发冠心病患者纤溶系统的变化

目的观察罗格列酮治疗前后糖尿病(DM)并发冠心病(CHD)患者纤溶系统的变化。方法 2型糖尿病合并冠心病患者100例随机分为常规治疗组(A组)和罗格列酮治疗组(B组)检测2组治疗前后一氧化氮(NO)、组织型纤溶酶原激活物(t-PA)和纤溶酶原激活物抑制剂(PAI-1)的含量变化。结果 A组、B组治疗后NO、t-PA浓度A组:(62.76±7.25)μmol/L、(32.75±9.36)μg/L;B组:(69.86±5.97)μmol/L、(40.62±10.56)μg/L]均显着高于治疗前A组:(42.73±6.14)μmol/L、(20.83±8.13)μg/L;B组:(41.76±6.65)μmol/L、(19.93±7.87)μg/L](t=2.545,t=2.911,P均<0.05);A组、B组治疗后PAI-1浓度(62.76±7.25)μg/L、(51.01±5.09)μg/L]均显着低于治疗前(88.23±9.91)μg/L、(89.46±9.15)μg/L](t=2.445,t=2.411,P均<0.05);B组治疗后PAI-1(51.01±5.09)μg/L明显低于A组(62.61±7.63)μg/L(t=2.589,P<0.05)。结论罗格列酮具有抗动脉粥样硬化作用对糖尿病并发冠心病患者是一个较好的治疗方法。

The Changes of Fibrinolytic System in Diabetes Mellitus with Coronary Heart Disease Treated by Rosiglitazone

Objective To observe the changes of fibrinolytic system in diabetes mellitus（DM） with coronary heart disease（CHD） treated by Rosiglitazone. Methods 100 cases of type 2 diabetes mellitus with coronary heart disease were divided into conventional therapy（A group）50 cases and Rosiglitazone treatment 03 group）50 cases, the contents of nitric oxide （NO）, tissue-tyep plasminogen activator （t-PA）and plasminogen activator inhibitor （PAI-1） in two groups were detected before treatment and after treatment. Results The contents of NO, t-PA in two group after treatment group A： （62.76±7.25）μmol/L, （32.75±9.36）μg/L; group B： （69.86±5.97）μmol/L, （40.62±10.56）μg/L, （61.76±5.25）μmol/L, （30.65±8.86）μg/L] were significantly higher than before av, atrnent（group A： （42.73±6.14）tunol/L, （20.83±8.13）μg/L; group B： （41.76±6.65）μmol/L, （19.93±7.87μg/L）]（t=-2.545, t=2.911,P all〈0.05）; The contents of PAI-1 （62.76±7.25）μg/L, （51.01±5.09）μg/L] alter treatment in two group were significantly lower than before treatment （88.23±9.91）μg/L, （89.46±9.15）μg/L] （t=2,445, t=-2.411, P all〈0.05）; The contents of PAI-1 （51.01±5.09） μg/L after treatment in group B were significantly lower than that（62.61±7.63）μg/L in group A （t=2.589, P〈0.05）. Conclusions Rosiglitazone ossess anti-atherosclerotic effects. It is better therapeutic method in diabetes mellitus with coronary heart disease